Aclarion, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aclarion, Inc. (NASDAQ: ACON) is a healthcare technology company that leverages magnetic resonance spectroscopy (MRS), proprietary biomarkers, and augmented intelligence algorithms to deliver noninvasive SaaS solutions for optimizing clinical treatments in the chronic low back and neck pain market; its flagship NOCISCAN platform analyzes the chemical composition of intervertebral discs to distinguish painful from nonpainful ones, generating individualized NOCI+/NOCI- scores on a 0-10 scale and supporting personalized treatment plans with reported 97% surgical success rates when pain-positive discs are addressed; the suite includes the NOCISCAN MRS Exam Protocol for extended lumbar MRI scans using commercial MRS pulse sequences, data transfer tools such as AMBRA Healthcare imaging platform and NOCIWEB interface, and the Post-Processor Suite featuring NOCICALC for raw data processing into spectra and biomarker calculations plus NOCIGRAM for NOCISCORE generation. Founded in 2008 and headquartered in Broomfield, Colorado, the company primarily serves physicians, radiologists, and healthcare providers in the United States while expanding commercially into the United Kingdom; it targets the $134.5 billion U.S. low back and neck pain sector affecting approximately 266 million people globally with degenerative spine disease. Recent developments include raising over $20 million in Q1 2025 to maintain nearly $15 million in cash reserves with zero debt, achieving full Nasdaq compliance for bid price and shareholder equity, fully funding the pivotal CLARITY trial with interim results expected in Q2 2026 and first patient enrollments at University of Miami Health System in September 2025, securing additional payer approvals in England covering 5.2 million lives, appointing Dan Isherwood as UK Commercial Director in November 2025 and Jason Brosniak as U.S. Eastern Commercial Director in December 2025 to drive adoption, publishing a NOCISCAN article in the International Journal of Spine Surgery's special pain issue on December 4, 2025, winning "Rising Star" at the 2025 Digital Health Awards, and pursuing partnerships with imaging providers like RadNet and MRI manufacturers.
Company News
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study